These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1068 related items for PubMed ID: 31958417

  • 21. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH, Lee JH, Lee JH, Kim DY, Park HS, Choi EJ, Ko SH, Seol M, Lee YS, Kang YA, Jeon M, Baek S, Kang YL, Kim SH, Yun SC, Kim H, Jo JC, Choi Y, Joo YD, Lim SN.
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [Abstract] [Full Text] [Related]

  • 22. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
    Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Sacchi N, van Lint MT, Bosi A, Gruppo Italiano Trapianti Midollo Osseo (GITMO).
    Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
    [Abstract] [Full Text] [Related]

  • 23. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
    Wegener A, Andersen NS, Friis LS, Petersen SL, Schjødt I, Kornblit B, Sengeløv H, Gjærde LK.
    Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
    [Abstract] [Full Text] [Related]

  • 24. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
    Brissot E, Labopin M, Labussière H, Fossard G, Chevallier P, Guillaume T, Yakoub-Agha I, Srour M, Bulabois CE, Huynh A, Chantepie S, Menard AL, Rubio MT, Ceballos P, Dulery R, Furst S, Malard F, Blaise D, Mohty M.
    Blood Cancer J; 2024 Feb 19; 14(1):31. PubMed ID: 38374026
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
    Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, Ho VT, Cutler C, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Alyea EP.
    J Clin Oncol; 2012 Sep 10; 30(26):3202-8. PubMed ID: 22869883
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
    Soltermann Y, Heim D, Medinger M, Baldomero H, Halter JP, Gerull S, Arranto C, Passweg JR, Kleber M.
    Ann Hematol; 2019 Jun 10; 98(6):1485-1493. PubMed ID: 30915500
    [Abstract] [Full Text] [Related]

  • 29. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.
    Kasper C, Sayer HG, Mügge LO, Schilling K, Scholl S, Issa MC, Höffken K.
    Bone Marrow Transplant; 2004 Jan 10; 33(1):65-9. PubMed ID: 14704658
    [Abstract] [Full Text] [Related]

  • 30. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A.
    Biol Blood Marrow Transplant; 2015 Jul 10; 21(7):1299-307. PubMed ID: 25797174
    [Abstract] [Full Text] [Related]

  • 31. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander AR.
    Exp Hematol; 2008 Aug 10; 36(8):1047-54. PubMed ID: 18456390
    [Abstract] [Full Text] [Related]

  • 32. Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia.
    Onishi Y, Mori T, Yamazaki H, Takenaka K, Yamaguchi H, Shingai N, Ozawa Y, Iida H, Ota S, Uchida N, Miyamoto T, Katayama Y, Kato J, Yoshioka S, Onizuka M, Ichinohe T, Atsuta Y, Adult Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Ann Hematol; 2021 Jan 10; 100(1):217-228. PubMed ID: 33033911
    [Abstract] [Full Text] [Related]

  • 33. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Rubio MT, Labopin M, Blaise D, Socié G, Contreras RR, Chevallier P, Sanz MA, Vigouroux S, Huynh A, Shimoni A, Bulabois CE, Caminos N, López-Corral L, Nagler A, Mohty M.
    Haematologica; 2015 May 10; 100(5):683-9. PubMed ID: 25769546
    [Abstract] [Full Text] [Related]

  • 34. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP, Cornetta K, Fausel CA, Farag SS.
    Biol Blood Marrow Transplant; 2011 Jun 10; 17(6):916-22. PubMed ID: 20932925
    [Abstract] [Full Text] [Related]

  • 35. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, Tamaki H, Inoue T, Hasei H, Iiboshi Y, Tazuke Y, Kawakami M, Kim EH, Soma T, Inoue T, Kawase I.
    Exp Hematol; 2008 Jan 10; 36(1):1-8. PubMed ID: 17920757
    [Abstract] [Full Text] [Related]

  • 36. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
    Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Finke J, ATG-Fresenius Trial Group.
    Blood; 2011 Jun 09; 117(23):6375-82. PubMed ID: 21467544
    [Abstract] [Full Text] [Related]

  • 37. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
    Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB.
    J Clin Oncol; 2017 Dec 20; 35(36):4003-4011. PubMed ID: 29040031
    [Abstract] [Full Text] [Related]

  • 38. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
    Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M.
    Cochrane Database Syst Rev; 2012 Sep 12; (9):CD009159. PubMed ID: 22972135
    [Abstract] [Full Text] [Related]

  • 39. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial.
    Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, Lopez-Yurda M, Versluijs AB, Zwaan CM, Lindemans CA, Boelens JJ.
    Lancet Haematol; 2022 Feb 12; 9(2):e111-e120. PubMed ID: 35114150
    [Abstract] [Full Text] [Related]

  • 40. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
    Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A.
    Cochrane Database Syst Rev; 2014 Jul 25; 2014(7):CD010280. PubMed ID: 25061777
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.